|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
11/1/2012 9:41:06 AM
SAN DIEGO, Oct. 31, 2012 /PRNewswire/ --Neurocrine Biosciences, Inc. (NBIX) today announced its financial results for the quarter and nine months ended September 30, 2012. For the third quarter of 2012, the Company reported a net loss of $3.1 million, or $0.05 loss per share, compared to net income of $31.4 million, or income of $0.56 per fully diluted share outstanding, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $4.5 million, or $0.07 loss per share, compared to net income of $36.2 million, or income of $0.64 per fully diluted share outstanding, for the first nine months of last year. During the third quarter of 2011, the Company recognized $30.0 million in milestone revenue under its collaboration agreement with Abbott.
|
|
|
|
|
|
|
|
|
|
|